-
In just two months,
Laminar Pharma achieves
the record figure in Spain
of 2 million euros with
its equity crowdfunding campaign
COMPANY
Laminar Pharma
LAMINAR PHARMA is a pioneering biopharmaceutical company that focuses on the discovery, rational design and initial clinical development of a new generation of medicines associated with a novel therapeutic approach: Membrane Lipid Therapy (MLT).
LAMINAR PHARMA arose in 2006 with the objective to develop breakthrough inventions patented by the University of the Balearic Islands (UIB) in Mallorca, Spain.
Membrane Lipid Theraphy (MLT)
Membrane Lipid Therapy (MLT) is an innovative and unique technology platform that is based on very specialized scientific knowledge, which allows us to confidently embark on the rational design of new molecules that regulate the structure and function of cell membrane lipids, and their associated proteins.
Recent advances in our understanding of lipid membrane structures and their interactions with peripheral signal transduction proteins have opened the way to develop synthetic lipids that target cell membranes. This approach has led to the development of novel and alternative therapeutic strategies for a number of important pathologies such as Cancer, Neurodegenerative diseases, Metabolic disorders or Inflammation.
Team
Prof. Pablo V. Escriba, PhD.
President & Founder
Antonio J. González, BSc.
COO
Adrian G. McNicholl, PhD.
CCO
Victoria Llado, PhD.
CSO
Daniel Bermejo, MSc.
Clinical Trial manager
Catalina Ana Rossello, PhD.
Clinical R&D projects
Paula Fernandez, PhD.
Director Oncology R&D
Manuel Torres, PhD.
Director Neurology R&D
Emilce Cano, Bs.
Project ManagerPRODUCTS
Novel products proposing alternative and innovative therapeutic strategies
Support Laminar Pharma
If you want to get involved in this promising project and join us as an investor, employee, researcher, collaborator, partner, licensee,… feel free to contact us and we will be happy to evaluate a potential mutually beneficial collaboration.